Boston Trust Walden Corp Makes New Investment in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Boston Trust Walden Corp bought a new stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 478,073 shares of the medical equipment provider's stock, valued at approximately $54,108,000. Boston Trust Walden Corp owned approximately 0.24% of Zimmer Biomet at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Premier Path Wealth Partners LLC grew its holdings in Zimmer Biomet by 21.0% in the first quarter. Premier Path Wealth Partners LLC now owns 12,472 shares of the medical equipment provider's stock worth $1,412,000 after purchasing an additional 2,168 shares during the period. State of Alaska Department of Revenue grew its stake in shares of Zimmer Biomet by 2.7% in the 1st quarter. State of Alaska Department of Revenue now owns 23,316 shares of the medical equipment provider's stock worth $2,638,000 after buying an additional 620 shares during the last quarter. Kingswood Wealth Advisors LLC grew its stake in shares of Zimmer Biomet by 20.0% in the 1st quarter. Kingswood Wealth Advisors LLC now owns 2,605 shares of the medical equipment provider's stock worth $295,000 after buying an additional 435 shares during the last quarter. FNY Investment Advisers LLC raised its stake in Zimmer Biomet by 90.5% during the first quarter. FNY Investment Advisers LLC now owns 400 shares of the medical equipment provider's stock valued at $45,000 after buying an additional 190 shares during the last quarter. Finally, QRG Capital Management Inc. boosted its holdings in Zimmer Biomet by 13.9% in the first quarter. QRG Capital Management Inc. now owns 6,775 shares of the medical equipment provider's stock worth $767,000 after acquiring an additional 827 shares in the last quarter. 88.89% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ZBH has been the subject of several recent analyst reports. Truist Financial set a $101.00 price target on Zimmer Biomet in a research report on Tuesday, May 6th. Morgan Stanley decreased their target price on shares of Zimmer Biomet from $115.00 to $95.00 and set an "equal weight" rating for the company in a report on Tuesday, May 6th. JPMorgan Chase & Co. dropped their target price on shares of Zimmer Biomet from $128.00 to $105.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 6th. BTIG Research reissued a "buy" rating on shares of Zimmer Biomet in a research report on Monday, April 14th. Finally, The Goldman Sachs Group lowered their price objective on Zimmer Biomet from $120.00 to $104.00 and set a "neutral" rating on the stock in a research report on Tuesday, May 6th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, Zimmer Biomet presently has a consensus rating of "Hold" and an average price target of $111.53.

Zimmer Biomet Stock Performance

Shares of NYSE ZBH traded up $0.67 during midday trading on Friday, hitting $91.22. 4,060,771 shares of the company's stock traded hands, compared to its average volume of 1,795,968. Zimmer Biomet Holdings, Inc. has a 1 year low of $89.22 and a 1 year high of $116.71. The stock has a market capitalization of $18.05 billion, a price-to-earnings ratio of 20.18, a price-to-earnings-growth ratio of 2.11 and a beta of 0.72. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.46 and a current ratio of 2.44. The firm has a fifty day moving average of $95.28 and a 200 day moving average of $102.80.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The medical equipment provider reported $1.81 EPS for the quarter, beating the consensus estimate of $1.77 by $0.04. Zimmer Biomet had a net margin of 11.86% and a return on equity of 12.73%. The firm had revenue of $1.91 billion during the quarter, compared to analyst estimates of $1.89 billion. During the same quarter in the prior year, the firm earned $1.94 EPS. The business's revenue for the quarter was up 1.1% compared to the same quarter last year. On average, analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Thursday, June 26th will be paid a dividend of $0.24 per share. The ex-dividend date of this dividend is Thursday, June 26th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.05%. Zimmer Biomet's dividend payout ratio (DPR) is presently 21.24%.

Insider Activity at Zimmer Biomet

In related news, insider Sang Yi sold 1,000 shares of the business's stock in a transaction that occurred on Wednesday, June 11th. The stock was sold at an average price of $95.00, for a total transaction of $95,000.00. Following the completion of the transaction, the insider now directly owns 20,424 shares in the company, valued at approximately $1,940,280. The trade was a 4.67% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.39% of the stock is currently owned by corporate insiders.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.